AAVantgarde

AAVantgarde Bio

AAVantgarde Bio develops proprietary viral vector platforms to deliver large genes for treating patients with inherited retinal diseases.

RhyGaze

This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.

Atsena Therapeutics

This clinical-stage company develops gene therapies to treat and prevent inherited retinal diseases for patients with conditions such as X-linked retinoschisis and Stargardt disease.

GenSight Biologics

This company develops gene therapies for patients suffering from neurodegenerative retinal diseases and central nervous system disorders.

Nightstar

This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.

Coave Therapeutics

The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.

Ikarovec

This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.

Beacon Therapeutics

This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.